![]() |
市場調查報告書
商品編碼
2009062
自動化放射性同位素合成模組市場報告:按類型、應用和地區分類(2026-2034 年)Automated Radiosynthesis Module Market Report by Type (Fully Automated, Semi-Automated), Application (Hospitals, Diagnostic Labs, Radiology Clinics, and Others), and Region 2026-2034 |
||||||
2025年,全球自動化放射性同位素合成模組市場規模達3,800萬美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到6,090萬美元,2026年至2034年的複合年成長率(CAGR)為5.22%。推動市場成長的主要因素包括:各種慢性病和心血管疾病(尤其是在老年族群)的盛行率不斷上升;醫療領域對用於產生斷層影像的PET和SPECT掃描儀的需求不斷成長;以及醫療領域的進步。
自動化放射合成模組是指用於合成示蹤分子和放射性同位素的先進醫療設備示蹤分子和放射性同位素適用於執行高階診斷和治療程序。這些模組還整合了正子斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 掃描儀。這些解決方案增強了斷層診斷方法的效用。與放射性示蹤劑和放射性藥物生產設備相比,它們在生產客製化、設備壽命、易於設定以及診斷和治療應用的操作效率方面具有優勢。此外,自動化放射合成模組可立即投入使用,並能改善治療監測活動。因此,它們被醫院、實驗室和診所的醫護人員廣泛使用。目前,自動化放射合成模組有全自動和半自動兩種商業版本可供選擇。
包括癌症和慢性阻塞性肺病(COPD)在內的各種慢性病和心血管疾病的日益普遍是推動市場成長的主要因素。此外,醫療領域對PET和SPECT斷層成像掃描儀的需求不斷成長,也帶動了對自動化放射合成模組的需求,從而促進了市場成長。同時,政府對分散式放射性示蹤劑生產的大規模投資也進一步推動了市場成長。此外,該產品諸多優勢(例如資本成本低、基礎設施要求低、性能優異)的日益普及也支撐著市場成長。這源於其應用、功能和有效性的重大技術進步,這些進步顯著促進了市場成長。此外,老年人口不斷增加,易患慢性病,以及全球死亡率上升也是推動市場成長的因素。其他利多市場成長的因素包括醫療基礎設施的顯著改善、近期研發活動的發展,以及主要企業之間為開發更有效率的新產品而建立的關鍵策略聯盟。除了醫療產業的顯著擴張外,政府和私人組織提供的資金和津貼,以促進自動化放射合成模組在各種應用中的普及,也推動了市場成長。
The global automated radiosynthesis module market size reached USD 38.0 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 60.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.22% during 2026-2034. The increasing prevalence of various chronic and cardiovascular diseases, especially amongst the geriatric population, along with the rising need for PET and SPECT scanners in the healthcare sector to create tomographic images and advancements in the healthcare sector represent some of the key factors driving the market.
Automated radiosynthesis module refers to advanced medical equipment designed to formulate the radioactive isotope with a tracer molecule that is suitable to perform intensive diagnostic and therapeutic procedures. The automated radiosynthesis module also employs positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scanners. These solutions improve the utility of tomographic imaging diagnostics methods. As compared to radiotracers and radiopharmaceutical units, it offers better scope for production customization, longer device life, setting-up convenience, and better operational efficiency while performing diagnosis and therapy administration. Along with this, the automated radiosynthesis module is readily usable and improves therapy monitoring activities. Consequently, it is extensively used across hospitals, laboratories, and clinics by healthcare practitioners. At present, automated radiosynthesis module is commercially available in full and semi-automated types.
The increasing prevalence of various chronic and cardiovascular diseases, including cancer and chronic obstructive pulmonary disorders (COPD), represents a prime factor driving the market growth. Additionally, the rising need for PET and SPECT scanners in the healthcare sector to create tomographic images have facilitated the demand for automated radiosynthesis module in the healthcare sector, which is acting as another growth-inducing factor. In line with this, the large-scale investments being made by several governments in the production of radiotracers in decentralized settings are further contributing to the market growth. Moreover, the rising awareness regarding the multiple product benefits, such as low capital cost, minimal infrastructural requirement, and optimal performance, is supporting the market growth. This can be further attributed to significant technological advancements in terms of its usage, features, and efficacy, which is considerably favoring the market growth. Additionally, the rising geriatric population, which is susceptible to chronic ailments, and the escalating mortality rates across the globe are propelling the market growth. Other factors, such as significant enhancements in the healthcare infrastructure, the recent research and development (R&D) activities, and the major strategic collaborations amongst key players to engineer new product alternatives with enhanced efficacy, are creating a positive outlook for the market growth. The market is also being driven by the significant expansion in the healthcare industry, along with funding and grants provided by government and private organizations to encourage the adoption of automated radiosynthesis module for various applications.
The report has also provided a detailed breakup and analysis of the automated radiosynthesis module market based on the type. This includes fully and semi-automated. According to the report, fully automated represented the largest segment.
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for automated radiosynthesis module. Some of the factors driving the North America automated radiosynthesis module market included the increasing prevalence of various chronic and cardiovascular diseases, significant technological advancements, and extensive research and development (R&D) activities.
The report has also provided a comprehensive analysis of the competitive landscape in the global automated radiosynthesis module market. Detailed profiles of all major companies have also been provided. Some of the companies covered includes Eckert & Ziegler Strahlen- und Medizintechnik AG, Elysia S.A., General Electric Company, IBA RadioPharma Solutions, Optimized Radiochemical Applications, SCINTOMICS Molecular, Applied Theranostics Technologies GmbH, Synthra GmbH, Trasis, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.